☆ 4.6 Article

Clinical Assessment of the Drug Interaction Potential of the Psychotropic Natural Product Kratom

CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Substance Abuse

A Case of Potential Pharmacokinetic Kratom-drug Interactions Resulting in Toxicity and Subsequent Treatment of Kratom Use Disorder With Buprenorphine/Naloxone

Hazel D. Brogdon et al.

Summary: This case report presents a patient who experienced serotonin syndrome after taking high doses of kratom along with venlafaxine and quetiapine, which resolved after discontinuation of these medications. The patient successfully discontinued kratom with the help of buprenorphine/naloxone.

JOURNAL OF ADDICTION MEDICINE (2022)

添加到收藏夹

Article Substance Abuse

Long-term buprenorphine treatment for kratom use disorder: A case series

Viktoriya R. Broyan et al.

Summary: Buprenorphine/naloxone can be an effective treatment option for kratom use disorder (KUD) according to the findings of this study.

SUBSTANCE ABUSE (2022)

添加到收藏夹

Article Substance Abuse

Pressure Necrosis Requiring Fasciotomy After Kratom Overdose

Natasha Tobarran et al.

Summary: This case report highlights the profound sedative effect of Kratom and the potential of pressure necrosis injury resulting in rhabdomyolysis and compartment syndrome requiring fasciotomy.

JOURNAL OF ADDICTION MEDICINE (2022)

添加到收藏夹

Article Plant Sciences

Kratom ( Mitragyna speciosa ) Validation: Quantitative Analysis of Indole and Oxindole Alkaloids Reveals Chemotypes of Plants and Products #

Preston K. Manwill et al.

Summary: Many consumers are using kratom to self-manage pain and opioid addiction. The alkaloid profile of kratom products and US-grown plants varies, with high levels of mitragynine being common. There are also different chemotypes of M. speciosa.

PLANTA MEDICA (2022)

添加到收藏夹

Review Pharmacology & Pharmacy

Understanding Kratom Use: A Guide for Healthcare Providers

Marc T. Swogger et al.

Summary: Kratom, a plant native to Southeast Asia, has been used for centuries as a mild stimulant and medicine. However, with its growing popularity in the West, concerns about its safety have been raised by US federal agencies, leading to criminalization in some states and cities. The lack of clinical trials on kratom has resulted in confusion among healthcare providers. Despite this, there is a growing body of peer-reviewed literature that can inform healthcare providers on how to discuss kratom use with consumers, while recognizing that it has not been approved as safe and effective for any disease. One important knowledge gap is the safety of combining kratom with other substances and medications. Therefore, this comprehensive overview aims to provide clarity for healthcare providers and patients.

FRONTIERS IN PHARMACOLOGY (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Clinical Pharmacokinetic Assessment of Kratom (Mitragyna speciosa), a Botanical Product with Opioid-like Effects, in Healthy Adult Participants

Rakshit S. Tanna et al.

Summary: This study assessed the pharmacokinetics of a low dose of kratom in healthy participants and found significant differences in the pharmacokinetics of different alkaloids. These differences may be attributed to variations in metabolism and distribution based on the alkaloids' specific configurations. The study provides a foundation for further research on the safety and effectiveness of kratom products.

PHARMACEUTICS (2022)

添加到收藏夹

Article Psychiatry

Kratom: Substance of Abuse or Therapeutic Plant?

David A. Gorelick

PSYCHIATRIC CLINICS OF NORTH AMERICA (2022)

添加到收藏夹

Article Substance Abuse

Prevalence and description of kratom (Mitragyna speciosa) use in the United States: a cross-sectional study

Jonathan Schimmel et al.

Summary: The estimated prevalence of past-year kratom use in the adult US population was 0.8%, with kratom users tending to have more serious substance abuse profiles compared to non-users or users of cannabis, alcohol, or cigarettes. This is the first description of kratom use at the national level.

ADDICTION (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Refined Prediction of Pharmacokinetic Kratom-Drug Interactions: Time-Dependent Inhibition Considerations

Rakshit S. Tanna et al.

Summary: Kratom's main alkaloid mitragynine has been shown to be a time-dependent inhibitor of hepatic and intestinal cytochrome P450 3A activity, potentially causing serious pharmacokinetic interactions with drugs. A static model predicted that mitragynine would increase systemic exposure to the probe drug midazolam by approximately 5.7-fold.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Modeling Pharmacokinetic Natural Product-Drug Interactions for Decision-Making: A NaPDI Center Recommended Approach

Emily J. Cox et al.

Summary: The article discusses the potential risks of botanical drugs on drug metabolism and provides a method for developing and applying models for pharmacokinetic interactions.

PHARMACOLOGICAL REVIEWS (2021)

添加到收藏夹

Article Chemistry, Medicinal

Activity of Mitragyna speciosa (Kratom) Alkaloids at Serotonin Receptors

Francisco Leon et al.

Summary: Research showed that kratom alkaloids have effects on serotonin receptors in vitro and in vivo, with paynantheine and speciogynine exhibiting high affinity for 5-HT(1A)Rs and 5-HT(2B)Rs. These alkaloids can produce antinociceptive properties through a mechanism independent of opioid receptors.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

添加到收藏夹

Article Substance Abuse

Kratom (Mitragyna speciosa): User demographics, use patterns, and implications for the opioid epidemic

Albert Garcia-Romeu et al.

DRUG AND ALCOHOL DEPENDENCE (2020)

添加到收藏夹

Article Chemistry, Medicinal

Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected lndole-Based Kratom Alkaloids

Samuel Obeng et al.

JOURNAL OF MEDICINAL CHEMISTRY (2020)

添加到收藏夹

Article Toxicology

Exploration of cytochrome P450 inhibition mediated drug-drug interaction potential of kratom alkaloids

Shyam H. Kamble et al.

TOXICOLOGY LETTERS (2020)

添加到收藏夹

Article Plant Sciences

The Chemistry of Kratom [Mitragyna speciosa]: Updated Characterization Data and Methods to Elucidate Indole and Oxindole Alkaloids

Laura Flores-Bocanegra et al.

JOURNAL OF NATURAL PRODUCTS (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Chemical composition and biological effects of kratom (Mitragyna speciosa): In vitro studies with implications for efficacy and drug interactions

D. A. Todd et al.

SCIENTIFIC REPORTS (2020)

添加到收藏夹

Article Substance Abuse

The internet market for Kratom, an opioid alternative and variably legal recreational drug

Rebecca S. Williams et al.

INTERNATIONAL JOURNAL OF DRUG POLICY (2020)

添加到收藏夹

Article Toxicology

Kratom exposures reported to United States poison control centers: 2011-2017

Sara Post et al.

CLINICAL TOXICOLOGY (2019)

添加到收藏夹

Article Public, Environmental & Occupational Health

Unintentional Drug Overdose Deaths with Kratom Detected-27 States, July 2016-December 2017

Emily O'Malley Olsen et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2019)

添加到收藏夹

Article Substance Abuse

u Kratom as a substitute for opioids: Results from an online survey

Marion A. Coe et al.

DRUG AND ALCOHOL DEPENDENCE (2019)

添加到收藏夹

Article Clinical Neurology

Characteristics of deaths associated with kratom use

John M. Corkery et al.

JOURNAL OF PSYCHOPHARMACOLOGY (2019)

添加到收藏夹

Letter Medicine, General & Internal

Deaths in Colorado Attributed to Kratom

Ken Gershman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Emergency Medicine

Kratom from Head to Toe-Case Reviews of Adverse Events and Toxicities

Emad Alsarraf et al.

CURRENT EMERGENCY AND HOSPITAL MEDICINE REPORTS (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

Inhibition of UGT2B7 Enzyme Activity in Human and Rat Liver Microsomes by Herbal Constituents

Nurul Huda Abdullah et al.

MOLECULES (2018)

添加到收藏夹

Article Pharmacology & Pharmacy

Rifampin modulation of xeno- and endobiotic conjugating enzyme mRNA expression and associated microRNAs in human hepatocytes

Brandon T. Gufford et al.

PHARMACOLOGY RESEARCH & PERSPECTIVES (2018)

添加到收藏夹

Article Chemistry, Medicinal

PXR mediated induction of CYP3A4, CYP1A2, and P-gp by Mitragyna speciosa and its alkaloids

Vamshi K. Manda et al.

PHYTOTHERAPY RESEARCH (2017)

添加到收藏夹

Article Pharmacology & Pharmacy

Fluoxetine- and Norfluoxetine-Mediated Complex Drug-Drug Interactions: In Vitro to In Vivo Correlation of Effects on CYP2D6, CYP2C19, and CYP3A4

J. E. Sager et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)

添加到收藏夹

Article Pharmacology & Pharmacy

Assessment of a Candidate Marker Constituent Predictive of a Dietary Substance-Drug Interaction: Case Study with Grapefruit Juice and CYP3A4 Drug Substrates

Garrett R. Ainslie et al.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)

添加到收藏夹

Article Chemistry, Medicinal

Physicochemical Space for Optimum Oral Bioavailability: Contribution of Human Intestinal Absorption and First-Pass Elimination

Manthena V. S. Varma et al.

JOURNAL OF MEDICINAL CHEMISTRY (2010)

添加到收藏夹

Review Biochemistry & Molecular Biology

Grapefruit Juice-Drug Interaction Studies as a Method to Assess the Extent of Intestinal Availability: Utility and Limitations

Michael Gertz et al.

CURRENT DRUG METABOLISM (2008)

添加到收藏夹

Article Plant Sciences

Inhibitory effects of kratom leaf extract (Mitragyna speciosa Korth.) on the rat gastrointestinal tract

Somsmorn Chittrakarn et al.

JOURNAL OF ETHNOPHARMACOLOGY (2008)

添加到收藏夹

Article Pharmacology & Pharmacy

Development of the Inje cocktail'' for high-throughput evaluation of five human cytochrome p450 Isoforms in vivo

J. Y. Ryu et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)

添加到收藏夹

Article Medicine, Research & Experimental

Antinociceptive effect of 7-hydroxymitragynine in mice:: Discovery of an orally active opioid analgesic from the Thai medicinal herb Mitragyna speciosa

K Matsumoto et al.

LIFE SCIENCES (2004)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.